title: Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report.
abstract: OBJECTIVE
  Optimal cytoreduction and response to chemotherapy have been associated with prolonged disease-free survival (DFS), but there are limited data regarding the clinical characteristics of those patients with optimal 5-year DFS (5YrDFS) outcomes.
  
  
  METHODS
  A case-control study was performed on 32 patients who were progression-free and alive at 5 years with advanced ovarian cancer 5YrDFS from 1993 to 2005 for this institutional review board-approved study. Matching controls were identified from the subset of patients who died or experienced disease progression before 5 years.
  
  
  RESULTS
  One hundred sixty patients were evaluated. There was no statistical difference between cases and controls in regard to neoadjuvant chemotherapy, grade, race, preoperative cancer antigen-125 level, optimal cytoreduction, operating room time, length of hospital stay, or total chemotherapy cycles in regard to 5YrDFS. If a patient achieved complete response after primary treatment, the likelihood of progression-free survival 5 years or longer is 7 times more likely, (odds ratio = 7.2 [95% confidence interval = 2.3-22.4]; P = 0.0006).
  
  
  CONCLUSIONS
  In this matched case-control analysis, complete response after primary treatment was the only significant factor associated with 5YrDFS. Further study is needed in patient and tumor characteristics to identify those patients who may have poor or favorable outcomes before treatment completion.
authors: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, James Graham Brown Cancer Center, University of Louisville Medical Center, Louisville, KY 40202, USA. mrmila01@louisville.edu
authors: Michael R
authors: MR
authors: Milam
authors: Robyn
authors: R
authors: Harrell
authors: Roland
authors: R
authors: Bassett
authors: Lynn P
authors: LP
authors: Parker
authors: Daniel S
authors: DS
authors: Metzinger
authors: Pedro T
authors: PT
authors: Ramirez
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000601:surgery; D010053:Ovary / Q000187:drug effects / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents